Insulet Co. (NASDAQ:PODD) Director John A. Fallon sold 9,000 shares of the company’s stock in a transaction on Wednesday, March 14th. The stock was sold at an average price of $84.10, for a total value of $756,900.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Shares of Insulet stock opened at $85.23 on Monday. The company has a market cap of $4,976.67, a price-to-earnings ratio of -185.28 and a beta of 1.56. Insulet Co. has a 1 year low of $38.43 and a 1 year high of $85.71. The company has a current ratio of 6.24, a quick ratio of 5.85 and a debt-to-equity ratio of 3.57.
Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.04). The business had revenue of $130.50 million for the quarter, compared to the consensus estimate of $125.16 million. Insulet had a negative net margin of 5.79% and a negative return on equity of 29.73%. The business’s revenue was up 26.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.16) EPS. equities research analysts forecast that Insulet Co. will post -0.3 earnings per share for the current fiscal year.
Several institutional investors have recently modified their holdings of the business. Rehmann Capital Advisory Group bought a new stake in shares of Insulet in the 4th quarter valued at $375,000. Xact Kapitalforvaltning AB bought a new stake in shares of Insulet in the 4th quarter valued at $381,000. Segall Bryant & Hamill LLC increased its position in shares of Insulet by 10.5% in the 4th quarter. Segall Bryant & Hamill LLC now owns 200,707 shares of the medical instruments supplier’s stock valued at $13,849,000 after buying an additional 19,105 shares in the last quarter. MetLife Investment Advisors LLC bought a new stake in shares of Insulet in the 4th quarter valued at $1,804,000. Finally, Castleark Management LLC bought a new stake in shares of Insulet in the 4th quarter valued at $16,289,000.
PODD has been the topic of several research reports. Raymond James Financial raised Insulet from a “market perform” rating to an “outperform” rating and set a $80.00 price objective on the stock in a report on Monday, January 8th. Zacks Investment Research downgraded Insulet from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. UBS raised Insulet from a “market perform” rating to an “outperform” rating in a report on Monday, January 8th. Barclays reaffirmed a “buy” rating and set a $78.00 price objective on shares of Insulet in a report on Wednesday, December 13th. Finally, BidaskClub downgraded Insulet from a “buy” rating to a “hold” rating in a report on Saturday, December 2nd. Eight analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $73.24.
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.